Szeimies R-M, Karrer S
Klinik für Dermatologie und Allergologie, Klinikum Vest GmbH, Akademisches Lehrkrankenhaus der Ruhr-Universität Bochum, Dorstener Str. 151, Recklinghausen, 45657, Deutschland.
Klinik und Poliklinik für Dermatologie, Universitätsklinikum Regensburg, Regensburg, Deutschland.
Hautarzt. 2021 Jan;72(1):27-33. doi: 10.1007/s00105-020-04737-6. Epub 2020 Dec 10.
Photodynamic therapy (PDT) is a licensed and established procedure for the treatment of actinic keratosis, basal cell carcinoma, and Bowen's disease, but there are several new and clinically relevant developments and trends. These concern on the one hand the main components of PDT, which are the photosensitizer and the light source. Furthermore, modifications and therapy combinations have been developed that lead to an improved therapeutic efficacy. An important aspect of field-directed PDT is also skin cancer prevention. Finally, PDT has been used successfully for nonlicensed indications including inflammatory diseases and skin rejuvenation. This article focuses on these new developments and on recent guideline recommendations.
光动力疗法(PDT)是一种已获许可且成熟的治疗光化性角化病、基底细胞癌和鲍恩病的方法,但目前有一些新的且与临床相关的进展和趋势。一方面,这些进展和趋势涉及光动力疗法的主要组成部分,即光敏剂和光源。此外,还开发了一些改进和联合治疗方法,从而提高了治疗效果。病灶靶向光动力疗法的一个重要方面也是皮肤癌预防。最后,光动力疗法已成功用于包括炎症性疾病和皮肤年轻化在内的非许可适应症。本文重点关注这些新进展以及近期的指南建议。